Ivabradine Zentiva

Ivabradine, the active ingredient in Ivabradine Zentiva, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic stable angina pectoris and chronic heart failure with reduced ejection fraction in appropriate adult patients who require heart rate reduction without negative inotropic effects.

GNH USA supplies Ivabradine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Ivabradine Zentiva acts on the cardiac If current to manage specific cardiovascular conditions. - Chronic stable angina pectoris: reduces frequency of angina attacks by lowering heart rate. - Chronic heart failure with reduced ejection fraction (NYHA II–III): improves exercise capacity and may reduce hospitalization by controlling heart rate. - Heart rate control in patients with angina: provides heart‑rate reduction without affecting contractility.

Ivabradine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 60 bpm. - Visual disturbances: transient luminous phenomena (phosphenes) reported. - Headache: mild to moderate intensity. - Dizziness: especially on standing.

Serious or Rare Side Effects: - Symptomatic bradycardia: may require medical intervention. - Atrial fibrillation: new‑onset arrhythmia observed in some patients. - Severe hypotension: marked drop in blood pressure. - Persistent visual impairment: rare cases of retinal issues.

Before initiating therapy, clinicians should consider several precautionary measures to ensure safe use of Ivabradine. - Assess baseline heart rate: confirm resting HR ≥ 60 bpm prior to start. - Monitor ECG: watch for excessive bradycardia during treatment. - Avoid strong CYP3A4 inhibitors: concomitant use can raise ivabradine levels. - Use with caution in hepatic impairment: dose adjustment may be needed. - Store at ambient temperature: keep in original packaging, protect from moisture.

Ivabradine interacts with several medicines; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Concurrent use of other If channel blockers (e.g., ranolazine): additive effect on heart rate.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may elevate plasma concentrations. - QT‑prolonging drugs (e.g., certain antiarrhythmics): monitor cardiac rhythm.